B2BROKER
26.10.2021 09:02:17 CEST | Business Wire | Press release
B2Broker, a leading technology and liquidity provider in the Forex and Crypto industry, has announced the introduction of a series of outstanding new conditions for its Margin and Crypto Spot liquidity offerings. With today’s announcement comes a new pricing structure that delivers an ultra competitive proposition which is unmatchable in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026005100/en/
B2Broker launched its initial Crypto CFD offering back in 2017, starting with 30 Crypto CFD pairs. The company was the first in this space to implement a Prime Broker business model approach in the Crypto CFD offering. Today, it offers a total of 115 Crypto pairs making it the industry’s leading Crypto CFD provider as well as a tier 1 liquidity provider in the Spot FX, Metals, Equity Indices, Commodities, Single Stocks, and ETFs space all from a single margin account.
To date, B2Broker is used by more than 50% of FX Retail Brokers/Props Houses/Funds, etc, who offer Crypto CFDs and require a main liquidity provider or secondary source of liquidity.
Margin Liquidity
As the popularity of margin trading continues to reach new heights, the new trading conditions from B2Broker will enable its clients to benefit from a whole range of new features and advantages. These include:
New Crypto CFDs
We have added a further 15 new crypto CFDs to our liquidity pool that have proved highly popular recently:
XRP, Cardano, Dogecoin, Solana, Polkadot, Chainlink, Polygon, Uniswap, HIBA INU, Algorand, Avalanche, Terra, Filecoin, Vechain and Maker.
Note: all trade against the USD.
New Margin Requirements
New margin requirements on major crypto CFDs have been decreased from 20% to 10% . This will allow greater opportunities for traders around the world to leverage our unbeatable conditions.
The list of symbols that we have applied changes to include:
BTC/USD, BCH/USD, ETH/USD, LTC/USD, XRP/USD
BTC/EUR, BCH/EUR, ETH/EUR, LTC/EUR, XRP/EUR
BTC/GBP, BCH/GBP, ETH/GBP, LTC/GBP
New Pricing Policy
New commercial offers have been introduced to serve all types of business models. Whether you need a white label solution, a FIX API/gateway connection or an enterprise solution, B2Broker offers a bespoke proposition that serves your business according to your requirements.
Our new Enterprise offering includes PrimeXM or OneZero HUB along with a liquidity solution that gives brokers greater flexibility in terms of managing their liquidity price streams and risk management solutions. The main idea behind this package is to offer broker dealers a solution where they will be able to use our liquidity along with leading HUBs/XCOREs in a more efficient and cost-effective way. For example, if you go directly to PrimeXM or OneZero and buy a Hub with them and then approach B2Broker to buy liquidity, it will prove to be more expensive than simply buying a single Enterprise pack from B2Broker.
The Enterprise liquidity solution is ideal for Brokers who have their own Trading Server such as MT5, MT4, C-Trader etc, and want to be able to manage their price streams, markups, swaps, risk management and more.
New Liquidity Pool Locations
Our liquidity pools are now based in main locations around the world such as LD4, NY4, TY3, SG1 and Mainland China (Beijing). You can choose the best suitable location for your API/Gateway connection.
For our WL clients based in LD4, we have created a global network of access servers which provide the lowest latency connection from any point in the world.
Liquidity Distribution
We offer liquidity distribution across the following platforms to cater for the broad-based demands of our clients PrimeXM, OneZero, FixAPI, MT5, MT4 for FX/CFD, Crypto CFDs etc and B2Trader, Rest API and WEBSocket for Crypto Spot liquidity.
Crypto Spot Liquidity
On the Crypto Spot liquidity side of things, we have introduced a range of outstanding new developments which are applicable to B2BX:
A. Revised ultra-competitive commission ladder which goes down to 0.04%.
B. In total we have enhanced the depth of order book to 100 levels per each side (Buy and Sell) to satisfy the requirements of major players. The compressed order book contains over 120 BTC with an average spread of just $7 USD and market impact of around $140 USD.
C. Increased our trading pairs to consist of additional stable coins and all the top tokens.
B2Broker CEO, Arthur Azizov commented, “We constantly seek to improve our offers and are positioned to offer an unbeatable pricing structure for our services, as well as other favourable conditions which will ultimately benefit our clients. Our liquidity services can be accessed quickly and easily with the most advantageous prices available within the industry and the highest level of technical support”.
B2Broker’s liquidity solutions are used by various types of financial institutions who benefit from our expertise and technology, and our ability to deliver customised liquidity solutions tailored to our clients exact needs. B2Broker offers liquidity on Spot FX, Metals, Commodities, Single Stocks with over 400 instruments, working as a PoP, rather than a market maker. We are therefore on the broker’s side at all times, enabling the best possible liquidity provision in keeping with our clients’ interests.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005100/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom